Phase 2: Active Initiatives
Phase 2 of the DIA AI Consortium is underway through December 2027, bringing together industry, health authorities, academia, technology organizations, and other stakeholders to advance responsible, practical uses of artificial intelligence in drug development. Building on Phase 1 foundational work, members are collaborating on implementation-oriented tools and guidance while exploring emerging AI applications in clinical trials.
Workstream 2: Innovation Incubator
What Phase 2 Is Working Toward
Phase 2 moves from foundational frameworks toward practical application and evaluation. The consortium is focused on: (1) translating Phase 1 work into reusable implementation resources; (2) exploring approaches to AI use-case classification, risk assessment, validation, monitoring, governance, and human oversight; (3) testing and refining approaches through member examples and real-world implementation experiences; and (4) examining emerging AI applications in clinical-trial design, execution, evidence generation, and related regulatory and operational considerations. Across both workstreams, members aim to share cross-sector learning and develop resources that remain useful as AI capabilities evolve.
Executive Committee
The consortium is a DIA-convened, pre-competitive collaboration guided by an Executive Committee and informed by participating organizations across the life sciences ecosystem. The Executive Committee supports strategic direction, prioritization, and alignment across workstreams, while DIA coordinates program activities and external engagement. Industry, academic, patient, technology, and health-authority perspectives inform the initiative’s work.
Active Workstreams
Building on Phase 1 foundations, Workstream 1 is exploring practical ways to apply AI frameworks within organizations. Areas under development include use-case intake and classification, risk scoring, organizational readiness, validation and testing, lifecycle monitoring, AI governance, and meaningful human oversight. Members are working on reusable playbooks, checklists, examples, and potential pilots to help test and refine approaches across different implementation settings.
Workstream 2 is examining emerging AI opportunities and adoption challenges in drug development, with an initial emphasis on accelerating clinical trials. Discussion areas include AI-enabled trial planning and execution, evidence generation, the evolving technology and regulatory landscape, and considerations such as human oversight, traceability, and the gap between technical capability and real-world deployment. Members are shaping a coordinated approach for assessing and communicating the state of the field.
The workstreams share insights on validation, governance, risk, evidence, and oversight to connect practical implementation needs with emerging applications.
Consortium Collaboration Model
Deliverables in Progress
Phase 2 work is progressing toward practical resources and shared analysis. Current areas of development include:
Exploration of member use cases and pilots to test and improve the usability of existing frameworks.
Analysis of emerging AI applications in clinical trials, including the distinction between technologies that are technically possible and those demonstrably adopted in practice.
Potential publications and other knowledge-sharing activities to communicate findings to the broader life sciences community.
Participating Organizations
Phase 2 brings together participating organizations spanning biopharmaceutical companies, health authorities, academic and research institutions, technology and consulting organizations, and patient perspectives. These diverse contributors support pre-competitive dialogue and practical cross-sector learning.
Consortium in Action
The DIA Global Annual Meeting creates opportunities for consortium members and the broader life sciences community to exchange perspectives on responsible AI and connect emerging research with real-world implementation challenges.Moments from AI Consortium sessions and meetings at the DIA Global Annual Meeting.
Recent Updates
Workstream 1 members are developing the direction for practical implementation resources, with discussion centered on classification and risk, validation, organizational readiness, governance, and human oversight.
OCTOBER 2026 | Exploring AI-enabled clinical-trial acceleration
Workstream 2 discussions have focused on emerging AI applications across the clinical-trial lifecycle and the challenge of evaluating promising technologies alongside evidence of real-world adoption.
AUGUST 2026 | Phase 2 collaboration underway
The consortium convened its Phase 2 kickoff, bringing members together around implementation-oriented priorities and an Innovation Incubator focused initially on clinical trials.




